Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.
   PubMed Web of Science ®Google Scholar
• Bandini M, Pompe RS, Marchioni M, et al. Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. World J Urol. 2018;36:7–13. doi:10.1007/s00345-017-2102-9
   PubMed Web of Science ®Google Scholar
• Marchioni M, Di Nicola M, Primiceri G, et al. New antiandrogen compounds compared to docetaxel for metastatic hormone sensitive prostate cancer: results from a network meta-analysis. J Urol. 2020;203:751–759. doi:10.1097/JU.0000000000000636
   PubMed Web of Science ®Google Scholar
• Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263–282. doi:10.1016/j.eururo.2020.09.046
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520. doi:10.1056/NEJMoa041318
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512. doi:10.1056/NEJMoa040720
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–160. doi:10.1016/S1470-2045(14)71205-7
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71:151–154. doi:10.1016/j.eururo.2016.07.032
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Lin P, Tombal B, et al. Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer from the PREVAIL trial. Eur Urol. 2020;78:347–357. doi:10.1016/j.eururo.2020.04.061
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422. doi:10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–1154. doi:10.1016/S0140-6736(10)61389-X
   PubMed Web of Science ®Google Scholar
• de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381:2506–2518. doi:10.1056/NEJMoa1911206
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983–992. doi:10.1016/S1470-2045(12)70379-0
   PubMed Web of Science ®Google Scholar
• Nadal R, Taplin M-E, Bellmunt J. Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial. Future Oncol. 2014;10:351–362. doi:10.2217/fon.13.275
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223. doi:10.1056/NEJMoa1213755
   PubMed Web of Science ®Google Scholar
• de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091–2102. doi:10.1056/NEJMoa1911440
   PubMed Web of Science ®Google Scholar
• Abida W, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020;38:3763–3772. doi:10.1200/JCO.20.01035
   PubMed Web of Science ®Google Scholar
• De Bono JS, Mehra N, Higano CS, et al. TALAPRO-1: phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC). JCO. 2021;39:93. doi:10.1200/JCO.2021.39.6_suppl.93
   PubMedGoogle Scholar
• Sweeney C, Bracarda S, Sternberg CN, et al. Ipatasertib plus Abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021;398:131–142. doi:10.1016/S0140-6736(21)00580-8
   PubMed Web of Science ®Google Scholar
• Crabb SJ, Griffiths G, Marwood E, et al. Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: a randomized, placebo-controlled phase II trial (ProCAID). JCO. 2021;39:190–201. doi:10.1200/JCO.20.01576
   PubMed Web of Science ®Google Scholar
• Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–1103. doi:10.1056/NEJMoa2107322
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38:395–405. doi:10.1200/JCO.19.01638
   PubMed Web of Science ®Google Scholar
• Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol. 2001;28:3–7. doi:10.1016/S0093-7754(01)90148-4
   PubMed Web of Science ®Google Scholar
• Duran GE, Wang YC, Francisco EB, et al. Mechanisms of resistance to cabazitaxel. Mol Cancer Ther. 2015;14:193–201. doi:10.1158/1535-7163.MCT-14-0155
   PubMed Web of Science ®Google Scholar
• Hager S, Ackermann CJ, Joerger M, Gillessen S, Omlin A. Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review. Ann Oncol. 2016;27:975–984. doi:10.1093/annonc/mdw156
   PubMed Web of Science ®Google Scholar
• Regan MM, O’Donnell EK, Kelly WK, et al. Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Ann Oncol. 2010;21:312–318. doi:10.1093/annonc/mdp308
   PubMed Web of Science ®Google Scholar
• Ross RW, Beer TM, Jacobus S, et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008;112:521–526. doi:10.1002/cncr.23195
   PubMed Web of Science ®Google Scholar
• Schaeffer EM, Srinivas S, Adra N, et al. NCCN guidelines® insights: prostate cancer, version 1.2023. J Natl Compr Canc Netw. 2022;20:1288–1298. doi:10.6004/jnccn.2022.0063
   PubMed Web of Science ®Google Scholar
• Corn PG, Heath EI, Zurita A, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019;20:1432–1443. doi:10.1016/S1470-2045(19)30408-5
   PubMed Web of Science ®Google Scholar
• Hikita K, Honda M, Shimizu R, et al. Efficacy of combination chemotherapy with docetaxel, estramustine and carboplatin in men with castration-resistant prostate cancer. Cancer Diagn Progn. 2021;1:451–457. doi:10.21873/cdp.10060
   PubMedGoogle Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. doi:10.1056/NEJMoa1014618
   PubMed Web of Science ®Google Scholar
• O’Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor Abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004;90:2317–2325. doi:10.1038/sj.bjc.6601879
   PubMed Web of Science ®Google Scholar
• Pal SK, Stein CA, Sartor O. Enzalutamide for the treatment of prostate cancer. Expert Opin Pharmacother. 2013;14:679–685. doi:10.1517/14656566.2013.775251
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–790. doi:10.1126/science.1168175
   PubMed Web of Science ®Google Scholar
• Loriot Y, Fizazi K, de Bono JS, Forer D, Hirmand M, Scher HI. Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: outcomes from the randomized controlled phase 3 AFFIRM trial. Cancer. 2017;123:253–262. doi:10.1002/cncr.30336
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–433. doi:10.1056/NEJMoa1405095
   PubMed Web of Science ®Google Scholar
• Morris MJ, Corey E, Guise TA, et al. Radium-223 mechanism of action: implications for use in treatment combinations. Nat Rev Urol. 2019;16:745–756. doi:10.1038/s41585-019-0251-x
   PubMed Web of Science ®Google Scholar
• Smith M, Parker C, Saad F, et al. Addition of radium-223 to Abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:408–419. doi:10.1016/S1470-2045(18)30860-X
   PubMed Web of Science ®Google Scholar
• Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2020;31:1119–1134. doi:10.1016/j.annonc.2020.06.011
   PubMed Web of Science ®Google Scholar
• Pene F, Courtine E, Cariou A, Mira J-P. Toward theragnostics. Crit Care Med. 2009;37:S50–58. doi:10.1097/CCM.0b013e3181921349
   PubMed Web of Science ®Google Scholar
• Hofman MS, Emmett L, Violet J, et al. TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU Int. 2019;124:5–13. doi:10.1111/bju.14876
   PubMed Web of Science ®Google Scholar
• Congregado B, Rivero I, Osmán I, Sáez C, Medina López R. PARP inhibitors: a new horizon for patients with prostate cancer. Biomedicines. 2022;10:1416. doi:10.3390/biomedicines10061416
   PubMed Web of Science ®Google Scholar
• Mateo J, Lord CJ, Serra V, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019;30:1437–1447. doi:10.1093/annonc/mdz192
   PubMed Web of Science ®Google Scholar
• Cleary JM, Aguirre AJ, Shapiro GI, D’Andrea AD. Biomarker-guided development of DNA repair inhibitors. Mol Cell. 2020;78:1070–1085. doi:10.1016/j.molcel.2020.04.035
   PubMed Web of Science ®Google Scholar
• Dan R, Van Allen EM, Y-M W, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–1228. doi:10.1016/j.cell.2015.05.001
   PubMed Web of Science ®Google Scholar
• Hussain M, Mateo J, Fizazi K, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383:2345–2357. doi:10.1056/NEJMoa2022485
   PubMed Web of Science ®Google Scholar
• Saad F, Armstrong AJ, Thiery-Vuillemin A, et al. PROpel: phase III trial of olaparib (ola) and Abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). JCO. 2022;40:11. doi:10.1200/JCO.2022.40.6_suppl.011
   Google Scholar
• Chi KN, Rathkopf DE, Smith MR, et al. Phase 3 MAGNITUDE study: first results of niraparib (NIRA) with Abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. JCO. 2022;40:12.
   PubMed Web of Science ®Google Scholar
• Braglia L, Zavatti M, Vinceti M, Martelli AM, Marmiroli S. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: still a potential druggable target? Biochim Biophys Acta Mol Cell Res. 2020;1867:118731. doi:10.1016/j.bbamcr.2020.118731
   PubMed Web of Science ®Google Scholar
• Batra A, Winquist E. Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer. Expert Opin Emerg Drugs. 2018;23:271–282. doi:10.1080/14728214.2018.1547707
   PubMed Web of Science ®Google Scholar
• Zhang T, George DJ, Armstrong AJ. Precision medicine approaches when prostate cancer akts up. Clin Cancer Res. 2019;25:901–903. doi:10.1158/1078-0432.CCR-18-2491
   PubMed Web of Science ®Google Scholar
• Kolinsky MP, Rescigno P, Bianchini D, et al. A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2020;31:619–625. doi:10.1016/j.annonc.2020.01.074
   PubMed Web of Science ®Google Scholar
• Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487–495. doi:10.1158/2159-8290.CD-11-0130
   PubMed Web of Science ®Google Scholar
• Duffy MJ, O’Grady S, Tang M, Crown J. MYC as a target for cancer treatment. Cancer Treat Rev. 2021;94:102154. doi:10.1016/j.ctrv.2021.102154
   PubMed Web of Science ®Google Scholar
• Beltran H, Oromendia C, Danila DC, et al. A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers. Clin Cancer Res. 2019;25:43–51. doi:10.1158/1078-0432.CCR-18-1912
   PubMed Web of Science ®Google Scholar
• Agarwal N, McGregor B, Maughan BL, et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol. 2022;23:899–909. doi:10.1016/S1470-2045(22)00278-9
   PubMed Web of Science ®Google Scholar
• Alpert E, Akhavan A, Gruzman A, et al. Multifunctionality of prostatic acid phosphatase in prostate cancer pathogenesis. Biosci Rep. 2021;41:BSR20211646. doi:10.1042/BSR20211646
   PubMed Web of Science ®Google Scholar
• Madan RA, Antonarakis ES, Drake CG, et al. Putting the pieces together: completing the mechanism of action jigsaw for sipuleucel-T. J Natl Cancer Inst. 2020;112:562–573. doi:10.1093/jnci/djaa021
   PubMedGoogle Scholar
• Handy CE, Antonarakis ES. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol. 2018;14:907–917. doi:10.2217/fon-2017-0531
   PubMed Web of Science ®Google Scholar
• Fujii T, Naing A, Rolfo C, Hajjar J. Biomarkers of response to immune checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol. 2018;130:108–120. doi:10.1016/j.critrevonc.2018.07.010
   PubMed Web of Science ®Google Scholar
• Barbosa AM, Gomes-Gonçalves A, Castro AG, Torrado E. Immune system efficiency in cancer and the microbiota influence. Pathobiology. 2021;88:170–186. doi:10.1159/000512326
   PubMed Web of Science ®Google Scholar
• Sharma P, Pachynski RK, Narayan V, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell. 2020;38:489–499.e3. doi:10.1016/j.ccell.2020.08.007
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1–10. doi:10.1200/JCO.19.02105
   PubMed Web of Science ®Google Scholar
• Yu EY, Kolinsky MP, Berry WR, et al. Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b/2 KEYNOTE-365 cohort B study. Eur Urol. 2022;82:22–30. doi:10.1016/j.eururo.2022.02.023
   PubMed Web of Science ®Google Scholar
• Stein MN, Fong L, Tutrone R, et al. ADXS31142 immunotherapy ± pembrolizumab treatment for metastatic castration-resistant prostate cancer: open-label phase I/II KEYNOTE-046 study. Oncologist. 2022;27:453–461. doi:10.1093/oncolo/oyac048
   PubMed Web of Science ®Google Scholar
• Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006. Prostate Cancer Prostatic Dis. 2011;14:177–183. doi:10.1038/pcan.2011.7
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879–882. doi:10.1093/jnci/djh141
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458–1468. doi:10.1093/jnci/94.19.1458
   PubMed Web of Science ®Google Scholar
• Blair JM, Zheng Y, Dunstan CR. RANK ligand. Int J Biochem Cell Biol. 2007;39:1077–1081. doi:10.1016/j.biocel.2006.11.008
   PubMed Web of Science ®Google Scholar
• Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655–1664. doi:10.1056/NEJMra030831
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813–822. doi:10.1016/S0140-6736(10)62344-6
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Armstrong AJ, Dehm SM, Luo J. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis. 2016;19:231–241. doi:10.1038/pcan.2016.17
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and Abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–1038. doi:10.1056/NEJMoa1315815
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Luber B, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015;1:582–591. doi:10.1001/jamaoncol.2015.1341
   PubMed Web of Science ®Google Scholar
• Sharp A, Coleman I, Yuan W, et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Invest. 2019;129:192–208. doi:10.1172/JCI122819
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Z, Gang X, Wang G. Liquid biopsy in prostate cancer: current status and future challenges of clinical application. Aging Male. 2021;24:58–71. doi:10.1080/13685538.2021.1944085
   PubMed Web of Science ®Google Scholar
• Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659–1665.
   PubMed Web of Science ®Google Scholar
• Conteduca V, Wetterskog D, Sharabiani MTA, et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or Abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol. 2017;28:1508–1516. doi:10.1093/annonc/mdx155
   PubMed Web of Science ®Google Scholar
• Goodall J, Mateo J, Yuan W, et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov. 2017;7:1006–1017. doi:10.1158/2159-8290.CD-17-0261
   PubMed Web of Science ®Google Scholar
• González-Billalabeitia E, Conteduca V, Wetterskog D, Jayaram A, Attard G. Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test. Prostate Cancer Prostatic Dis. 2019;22:195–205. doi:10.1038/s41391-018-0098-x
   PubMed Web of Science ®Google Scholar
• Szilágyi M, Pös O, Márton É, et al. Circulating cell-free nucleic acids: main characteristics and clinical application. Int J Mol Sci. 2020;21:6827. doi:10.3390/ijms21186827
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–10518. doi:10.1073/pnas.0804549105
   PubMed Web of Science ®Google Scholar
• Urabe F, Matsuzaki J, Yamamoto Y, et al. Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer. Clin Cancer Res. 2019;25:3016–3025. doi:10.1158/1078-0432.CCR-18-2849
   PubMed Web of Science ®Google Scholar
• Liu H-P, Lai H-M, Guo Z. Prostate cancer early diagnosis: circulating microRNA pairs potentially beyond single microRNAs upon 1231 serum samples. Brief Bioinform. 2021;22:bbaa111. doi:10.1093/bib/bbaa111
   PubMed Web of Science ®Google Scholar
• Al-Qatati A, Akrong C, Stevic I, et al. Plasma microRNA signature is associated with risk stratification in prostate cancer patients. Int J Cancer. 2017;141:1231–1239. doi:10.1002/ijc.30815
   PubMed Web of Science ®Google Scholar
• Rodríguez SVM, García-Perdomo HA. Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: a systematic review and meta-analysis. Can Urol Assoc J. 2020;14:E214–E219. doi:10.5489/cuaj.6008
   PubMed Web of Science ®Google Scholar
• Merdan S, Tomlins SA, Barnett CL, et al. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy. Cancer. 2015;121:4071–4079. doi:10.1002/cncr.29611
   PubMed Web of Science ®Google Scholar
• van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19:213–228. doi:10.1038/nrm.2017.125
   PubMed Web of Science ®Google Scholar
• McKiernan J, Donovan MJ, Margolis E, et al. A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with prostate-specific antigen 2–10ng/mL at initial biopsy. Eur Urol. 2018;74:731–738. doi:10.1016/j.eururo.2018.08.019
   PubMed Web of Science ®Google Scholar
• Margolis E, Brown G, Partin A, et al. Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies. Prostate Cancer Prostatic Dis. 2022;25:296–301. doi:10.1038/s41391-021-00456-8
   PubMed Web of Science ®Google Scholar
• Ferraldeschi R, Nava Rodrigues D, Riisnaes R, et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with Abiraterone acetate. Eur Urol. 2015;67:795–802. doi:10.1016/j.eururo.2014.10.027
   PubMed Web of Science ®Google Scholar